Kolonin Mikhail G, Bover Laura, Sun Jessica, Zurita Amado J, Do Kim-Anh, Lahdenranta Johanna, Cardó-Vila Marina, Giordano Ricardo J, Jaalouk Diana E, Ozawa Michael G, Moya Catherine A, Souza Glauco R, Staquicini Fernanda I, Kunyiasu Akihiko, Scudiero Dominic A, Holbeck Susan L, Sausville Edward A, Arap Wadih, Pasqualini Renata
The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer Res. 2006 Jan 1;66(1):34-40. doi: 10.1158/0008-5472.CAN-05-2748.
A collection of 60 cell lines derived from human tumors (NCI-60) has been widely explored as a tool for anticancer drug discovery. Here, we profiled the cell surface of the NCI-60 by high-throughput screening of a phage-displayed random peptide library and classified the cell lines according to the binding selectivity of 26,031 recovered tripeptide motifs. By analyzing selected cell-homing peptide motifs and their NCI-60 recognition patterns, we established that some of these motifs (a) are similar to domains of human proteins known as ligands for tumor cell receptors and (b) segregate among the NCI-60 in a pattern correlating with expression profiles of the corresponding receptors. We biochemically validated some of the motifs as mimic peptides of native ligands for the epidermal growth factor receptor. Our results indicate that ligand-directed profiling of tumor cell lines can select functional peptides from combinatorial libraries based on the expression of tumor cell surface molecules, which in turn could be exploited as "druggable" receptors in specific types of cancer.
源自人类肿瘤的60种细胞系(NCI-60)已被广泛用作抗癌药物发现的工具。在此,我们通过对噬菌体展示随机肽库进行高通量筛选,对NCI-60的细胞表面进行了分析,并根据回收的26,031个三肽基序的结合选择性对细胞系进行了分类。通过分析选定的细胞归巢肽基序及其NCI-60识别模式,我们确定其中一些基序(a)类似于已知为肿瘤细胞受体配体的人类蛋白质结构域,并且(b)在NCI-60中以与相应受体表达谱相关的模式分离。我们通过生化方法验证了其中一些基序作为表皮生长因子受体天然配体的模拟肽。我们的结果表明,基于肿瘤细胞表面分子的表达,对肿瘤细胞系进行配体导向分析可以从组合文库中筛选出功能性肽,这些肽进而可作为特定类型癌症中的“可药物化”受体加以利用。